PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
== Role in B and T Cell Production and Homeostasis == Reticular cells play a central role in the development and homeostasis of both B and T lymphocytes. Within the lymph node, fibroblastic reticular cells form a 3D network that acts as both a structural outline and communication network for immune signaling. Immune signaling is crucial to survival of the human body. These specific structures allow T cells to migrate efficiently through the lymph node, scanning for antigens presented by dendritic cells while doing so. In the T-cell zones of lymph nodes as described above, reticular cells secrete interleukin-7 (IL-7). This is a cytokine critical for both the maintenance and survival of T cells. Link et al. (2007) demonstrated that when lymph nodes or reticular cell-derived IL-7 are disrupted, T cell survival decreases significantly. Additionally, these same reticular cells release CCL19, a chemokine that regulates T cell movement and also helps maintain overall T-cell well-being. The balance between these two signaling molecules ensures that T cells remain functional and ready to respond rapidly to presented antigens. Beyond just T cells, reticular cells are equally essential for B cell homeostasis. According to Cremasco et al. (2014), reticular cells produce BAFF (B-cell activating factor), a survival signal that helps to sustain B cell populations within lymphoid follicles. When reticular cells were experimentally removed, it was shown that B cell organization collapses.
In November 2011, the results of a double-blind, placebo-controlled study (financed by Hythiam and carried out at UCLA) were published in the peer-reviewed journal Addiction. It concluded that Gabasync is ineffective: "The PROMETA protocol, consisting of flumazenil, gabapentin, and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment, or reducing methamphetamine craving."
== Preparation and reactivity == Dimercaptosuccinic acid may be prepared by reacting acetylenedicarboxylic acid with sodium thiosulfate or thioacetic acid followed by hydrolysis. The dimethyl ester is also known. Meso 2,3-dimercaptosuccinic acid binds to "soft" heavy metals such as Hg2+ and Pb2+, mobilizing these ions for excretion. It binds to metal cations through the thiol groups, which ionize upon complexation.
Pd-catalyzed Tyr O-alkylation By using a pre-formed electrophilic π-allylpalladium(II) reagent derived from allylic acetate or carbamate precursors, selective allylic alkylation of tyrosines can be achieved in aqueous solution at room temperature and in the presence of cysteines.
=== Background === In the mid-1960s, the United States and Western Europe planned airliners seating twice the then-maximum of some 200 passengers. They were known as airbuses at the time. The Soviet leadership wanted to match them with an aerobus (Russian: аэробус). Alongside the propaganda motive, the USSR genuinely needed an aerobus. Aeroflot expected over 100 million passengers a year within a decade (the 100th million annual passenger was indeed carried on 29 December 1976.) First to respond was OKB-153, the bureau led by Oleg Antonov. It proposed a 724-seat version of the An-22 airlifter. The project was promoted until 1969, ultimately with a 605-passenger interior (383 on the upper deck and 223 on the lower). It did not go ahead due to fears that it would be old-fashioned and because the Kiev-based bureau was close to the deposed Nikita Khrushchev.
Sources: en.wikipedia.org
== Early career == Shambhu Nath De was born in Hooghly District, West Bengal, India. His father Mr Dasarathi De was a not so successful businessman. Supported by his uncle Asutosh De, De completed the Matriculation examination with distinction from Garbati High School that helped him to get the District scholarship as well as to pursue further education in Hooghly Mohsin College, which was then affiliated with the prestigious University of Calcutta. His higher education was supported by Kestodhan Seth, who identified De as an extraordinary student. De passed his M.B. examination in 1939 from Calcutta Medical College and completed a Diploma in Tropical Medicine (DTM) in 1942. Soon after graduation he joined Calcutta Medical College as a Demonstrator of Pathology and initiated his research under Professor B. P. Tribedi. In 1947, De joined as a PhD student under Sir Roy Cameron at the Department of Morbid Anatomy, University College Hospital Medical School, London, and obtained his PhD degree in Pathology in 1949. After his return, De worked on pathogenesis of cholera and started publishing his findings. In 1955, De became the Head of Pathology and Bacteriology Division of the Calcutta Medical College, which he continued until his retirement. De published more than 30 research papers and has written an excellent monograph on cholera and its pathogenesis.
=== Prevalence in rain, soil, water bodies, and air === In 2022, levels of at least four perfluoroalkyl acids (PFAAs) in rain water worldwide greatly exceeded the EPA's lifetime drinking water health advisories as well as comparable Danish, Dutch, and European Union safety standards, leading to the conclusion that "the global spread of these four PFAAs in the atmosphere has led to the planetary boundary for chemical pollution being exceeded". The most common PFAS found in the environment is Trifluoroacetic acid (TFA). Its presence is ubiquitous in the environment, especially in aquatic ecosystems, where it persists with increasing concentrations globally. It had been thought that PFAAs would eventually end up in the oceans, where they would be diluted over decades, but a field study published in 2021 by researchers at Stockholm University found that they are often transferred from water to air when waves reach land, are a significant source of air pollution, and eventually get into rain. The researchers concluded that pollution may impact large areas. Soil is also contaminated and the chemicals have been found in remote areas such as Antarctica. Soil contamination can result in higher levels of PFAS found in foods such as white rice, coffee, and animals reared on contaminated ground. In 2024, a worldwide study of 45,000 groundwater samples found that 31% of samples contained levels of PFAS that were harmful to human health; these samples were taken from areas not near any obvious source of contamination.
The Russian interior ministry placed Zelenskyy in its list of wanted criminals. Ukraine claimed to have shot down a Russian Su-25 fighter jet over Donetsk Oblast. The Russian defence ministry claimed to have shot four ATACMS missiles over Crimea. A court in Russia sentenced a Ukrainian POW captured during the Siege of Mariupol to 18 years imprisonment for membership in the Azov Battalion.
== Background == As the second largest class of enzymes behind ubiquitin ligases and responsible for ~2% of any organism's genes, proteases have drawn the attention of biologists to develop a field aimed at identifying and quantifying their roles in biology. First coined in 2000 by the Overall Lab in McQuibban et al., degradomics was described as linking proteases to substrates on a proteome basis. The discoveries of novel roles for proteases and breakthroughs in protease-substrate discovery would be summarized later by Dr. Carlos Lopez-Otin and Dr. Chris Overall, introducing degradomics on a system-wide scale. They collated the current and emerging techniques available to describe proteolysis. By drawing attention to how proteolysis serves as an additional irreversible mechanism by which cells could achieve control over biological processes, they outlined the necessity of studying proteases for their functional relevance in processing bioactive molecules. These bioactive molecules play roles in coagulation, complement activation, DNA replication, cell-cycle control, cellular proliferation and migration, hemostasis, immunity, and apoptosis. The degradome was broken down into two concepts, the first referring the entire profile of proteases expressed under by a cell, tissue, or organism under defined circumstances. The second definition applies specifically to the full substrate repertoire of a certain protease in a cell, tissue, or organism. Dr. Overall's group would go on to annotate the complete human and mouse protease-inhibitor degradomes in 2003.
== Further reading == May RM, Anderson RM (1991). Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press. ISBN 0-19-854040-X. Vynnycky E, White RG, eds. (2010). An Introduction to Infectious Disease Modelling. Oxford: Oxford University Press. ISBN 978-0-19-856576-5. Capasso V (2008). Mathematical Structures of Epidemic Systems. 2nd Printing. Heidelberg: Springer. ISBN 978-3-540-56526-0. Carlson CS, Rubin DM, Heikkilä V, Postema M (2021). "Extracting transmission and recovery parameters for an adaptive global system dynamics model of the COVID-19 pandemic". 2021 IEEE Africon (PDF). pp. 456–459. doi:10.1109/AFRICON51333.2021.9570946. ISBN 978-1-6654-1984-0. S2CID 239899862.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.